Study of two drugs for advanced thyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests two oral medications, avutometinib and defactinib, for people with advanced thyroid cancer that has specific genetic changes. The goal is to see if these drugs can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of thyroid cancer that has come back or spread and cannot be removed with surgery.
- Your tumor must have certain genetic changes, like RAS or BRAF mutations, that make it likely to respond to the study drugs.
- Your cancer must be growing, as shown by scans or symptoms, within the last 14 months (for most participants).
- You must be able to swallow pills and have adequate liver, kidney, and heart function.
- You must agree to have two biopsies of your tumor, unless it is not safe or possible.
- You must not have had certain types of cancer treatment within 4 weeks of starting the study, and you must not have taken certain other drugs (like MEK inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral and infused drugs to slow or shrink advanced thyroid cancer that has stopped responding to initial treatment. It may offer a new option for people with limited choices.
This trial tests an investigational drug called MRG003 added to your current treatment for advanced thyroid cancer that has stopped responding. It may help people with specific types of thyroid cancer and certain tumor markers.
This trial tests two oral drugs, avutometinib and defactinib, for people with a specific type of stomach cancer called diffuse gastric cancer. The goal is to see if these drugs can help shrink or slow the cancer.
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.